1. Home
  2. AHCO vs ORKA Comparison

AHCO vs ORKA Comparison

Compare AHCO & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdaptHealth Corp.

AHCO

AdaptHealth Corp.

HOLD

Current Price

$10.51

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$27.91

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHCO
ORKA
Founded
2012
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AHCO
ORKA
Price
$10.51
$27.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$13.60
$48.20
AVG Volume (30 Days)
1.2M
719.0K
Earning Date
02-24-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.55
N/A
Revenue
$3,255,213,000.00
N/A
Revenue This Year
$1.07
N/A
Revenue Next Year
$6.49
N/A
P/E Ratio
$18.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.11
$5.49
52 Week High
$11.63
$32.64

Technical Indicators

Market Signals
Indicator
AHCO
ORKA
Relative Strength Index (RSI) 59.96 44.15
Support Level $9.53 $25.23
Resistance Level $10.38 $32.64
Average True Range (ATR) 0.32 2.15
MACD -0.03 -0.55
Stochastic Oscillator 82.03 34.55

Price Performance

Historical Comparison
AHCO
ORKA

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: